Re: Back to the draw­ing board for triple-neg­a­tive breast can­cer tar­gets, re­searchers pro­pose new com­bo ap­proach.

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Telepanel

Rank: Treasurer [?]

Points: 1140 [?]

Votes: 22 Score: 2.2 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Back to the drawing board for triple-negative breast cancer targets, researchers propose new combo approach.

in response to

Re: Back to the drawing board for triple-negative breast cancer targets, researchers propose new combo approach.

narmac

posted on Apr 01, 2020 03:58PM

Had a conversation with mgmt a couple of months ago 're Rv x and asked about Zenith was told the Breast trial after a Late start was showing great results and that the Prostate trial was to be presented at end of April...that conference is cal I had PM to a poster at that time as most were only interested in Rvx

4 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Re: Back to the draw­ing board for triple-neg­a­tive breast can­cer tar­gets, re­searchers pro­pose new com­bo ap­proach.

Re: Back to the drawing board for triple-negative breast cancer targets, researchers propose new combo approach.